.Sanofi is actually still bented on taking its numerous sclerosis (MS) med tolebrutinib to the FDA, managers have told Intense Biotech, even with the BTK
Read moreSanofi’s $80M bet on Fulcrum dystrophy medication finishes in period 3 fail
.Simply four months after Sanofi wager $80 thousand in ahead of time cash on Pivot Therapeutics’ losmapimod, the program has ended in a phase 3
Read moreSanofi picks brand-new CSO coming from in-stealth biotech
.After a couple of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma fold, occupying the top science place at Sanofi.Quigley will
Read moreSanofi pays $110M upfront for late-stage radioligand therapy
.Sanofi has brought in a late access to the radioligand event, spending one hundred million euros ($ 110 thousand) beforehand for international liberties to a
Read moreSanofi flunks MS research study, dealing an additional strike to Denali treaty
.Sanofi has actually ceased a stage 2 trial of Denali Therapeutics-partnered oditrasertib in various sclerosis. The French drugmaker tore the RIPK1 inhibitor ordeal from its
Read moreSangamo slashes time to market for Fabry gene treatment as FDA accepts sped up confirmation bundle
.Sangamo Rehabs has actually recognized a faster way to market for its own Fabry illness candidate, lining up with the FDA on a pathway that
Read moreSage lays off one-half of R&D group and also shocks C-suite once more
.Sage Therapies’ most current effort to diminish its own pipe as well as staff are going to find a third of the biotech’s workers heading
Read moreRoivant introduces brand-new ‘vant’ to evolve Bayer hypertension med
.Matt Gline is actually back along with a brand-new ‘vant’ business, after the Roivant Sciences chief executive officer paid for Bayer $14 thousand upfront for
Read moreRoche scraps $120M tau possibility, returning legal rights to UCB
.Roche has sent back the civil liberties to UCB’s anti-tau antibody bepranemab, bowing out a $120 thousand bet on the Alzheimer’s ailment medicine applicant on
Read moreRoche is holding out hopes that its injectable being overweight possibility might ultimately show 25% fat burning in late-stage trial
.Roche is actually keeping out hopes that its injectable excessive weight possibility could eventually illustrate 25% fat burning in late-stage tests, the pharma’s head of
Read more